CapsulesClinical Overview
Rabeprazole Sodium (20mg enteric-coated) and Domperidone (10mg/30mg sustained-release) is a rapid-onset PPI and prokinetic combination. Rabeprazole has a higher pKa (~5.0) than other PPIs, allowing faster activation at higher pH and achieving rapid, potent inhibition of gastric H+/K+-ATPase pumps from the first dose. Domperidone provides dopamine D2 antagonism to enhance lower esophageal sphincter tone and accelerate gastric emptying. Indicated for erosive esophagitis, GERD, hypersecretory conditions, and dyspeptic symptom complexes (nausea, postprandial fullness, acid regurgitation).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily in the morning, 30 minutes before breakfast with water. Swallow the capsule whole; do not chew or crush the beads inside. Duration is typically 4 to 8 weeks.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Headache, dry mouth, diarrhea, flatulence, abdominal pain, benign fundic gland polyps (long term). Rare/Severe: Hyperprolactinemia (galactorrhea, amenorrhea), ventricular arrhythmias/QTc prolongation (domperidone), hypomagnesemia, and C. difficile-associated colitis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in patients with prolonged cardiac QT intervals, severe hepatic failure, GI perforation, or prolactinoma. Exercise caution in elderly patients (>60 years) taking domperidone doses exceeding 30mg daily due to increased risk of ventricular arrhythmia.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Domperidone Tablets 10 mg
Domperidone Tablets (10mg) and Suspension (5mg/5ml) is a peripheral dopamine D2 receptor antagonist antiemetic and prokinetic on the WHO Model List framework. Because it does not readily cross the blood-brain barrier, it acts primarily at the chemoreceptor trigger zone (outside the blood-brain barrier) and gastrointestinal tract, stimulating upper GI motility, increasing LES pressure, and accelerating gastric emptying. Indicated for relief of symptoms of nausea and vomiting of various etiologies, and diabetic gastroparesis.
Domperidone Suspension 5mg per 5ml
Domperidone Tablets (10mg) and Suspension (5mg/5ml) is a peripheral dopamine D2 receptor antagonist antiemetic and prokinetic on the WHO Model List framework. Because it does not readily cross the blood-brain barrier, it acts primarily at the chemoreceptor trigger zone (outside the blood-brain barrier) and gastrointestinal tract, stimulating upper GI motility, increasing LES pressure, and accelerating gastric emptying. Indicated for relief of symptoms of nausea and vomiting of various etiologies, and diabetic gastroparesis.
Omeprazole 20mg + Domperidone 10mg Capsules
Omeprazole (20mg gastro-resistant) and Domperidone (10mg/30mg sustained-release) is a cornerstone fixed-dose PPI and prokinetic combination on the WHO Model List framework. Omeprazole irreversibly suppresses gastric acid secretion by inhibiting parietal cell H+/K+-ATPase. Domperidone blocks peripheral dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, stimulating gastric motility and preventing acid reflux. Indicated for gastroesophageal reflux disease, non-ulcer dyspepsia, and peptic ulcer disease accompanied by nausea, fullness, or vomiting.
Rabeprazole Gastro Resistant Tablets 20 mg
Rabeprazole Gastro-Resistant Tablets (20mg) is a second-generation proton pump inhibitor on the WHO Model List of Essential Medicines. It binds to gastric H+/K+-ATPase with high potency and dissociates more rapidly than first-generation PPIs, producing faster acid inhibition within hours of the first dose. Indicated for acute duodenal and gastric ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome.